Alnylam Pharmaceuticals Q3 Non-GAAP Net Income, Revenue Rise; Fiscal 2026 Net Product Sales Outlook Kept

08:46 AM EDT, 10/29/2026 (MT Newswires) -- Alnylam Pharmaceuticals (ALNY) reported Q3 non-GAAP net income Thursday of $16.26 per diluted share, up from $3.19 a year earlier. Revenue for the quarter ended Sept. 30 was $1.46 billion, up from $1.25 billion a year earlier. Analysts polled by FactSet expected $1.43 billion. The company said it continues to expect fiscal 2026 net product revenue in the range of $4.70 billion to $5.10 billion.